1. Axitinib as a third or further line of treatment in renal cancer. A single institution experience
- Author
-
Aristotelis Bamias, Flora Zagouri, G. Tsironis, Meletios A. Dimopoulos, Maria Kaparelou, Konstantinos Koutsoukos, Efi Skafida, Michalis Liontos, Anastasios Kyriazoglou, Anna Tsiara, Abis Cohen, Sofia Fontara, and Roubini Zakopoulou
- Subjects
Adult ,Male ,0301 basic medicine ,Oncology ,medicine.medical_specialty ,Axitinib ,medicine.drug_class ,Urology ,lcsh:RC870-923 ,Tyrosine-kinase inhibitor ,03 medical and health sciences ,0302 clinical medicine ,Renal cell carcinoma ,Internal medicine ,medicine ,Humans ,Long responders ,Adverse effect ,Carcinoma, Renal Cell ,Protein Kinase Inhibitors ,Aged ,Retrospective Studies ,business.industry ,Cancer ,Retrospective cohort study ,mRCC ,General Medicine ,Middle Aged ,lcsh:Diseases of the genitourinary system. Urology ,medicine.disease ,Kidney Neoplasms ,Regimen ,030104 developmental biology ,TKIs ,Reproductive Medicine ,beyond second line ,030220 oncology & carcinogenesis ,Female ,business ,Kidney cancer ,Research Article ,medicine.drug - Abstract
Background Kidney cancer is a lethal neoplasm that affects several thousands of people every year. Renal cell carcinoma (RCC) is the most common histologic type. Recent developments in the therapeutic approach include antiangiogenic targeted approaches and Immunotherapy. Thus, the therapeutic algorithm of RCC patients and the survival outcomes have changed dramatically. Methods Herein we present a retrospective study of the patients treated in our Department with an antiangiogenic agent -Axitinib, a tyrosine kinase inhibitor- as a third or further line treatment. Statistical analysis was performed with SPSS, including the available clinicopathological data of the patients included. Results Axitinib was found to be active in patients who received this treatment beyond second line. The toxicity profile of this regimen did not reveal any unknown adverse events. Conclusions Our real world data reflect that axitinib is a safe and effective option, even beyond the second line.
- Published
- 2020